Fifth Third Bancorp Invests $499,000 in Amneal Pharmaceuticals, Inc. $AMRX

Posted by Geri Gentry on Jul 30th, 2026

Fifth Third Bancorp bought a new position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) in the 1st quarter, HoldingsChannel.com reports. The firm bought 40,151 shares of the company’s stock, valued at approximately $499,000.

Several other hedge funds also recently added to or reduced their stakes in the stock. Oregon Public Employees Retirement Fund acquired a new stake in Amneal Pharmaceuticals during the first quarter worth approximately $482,000. New York State Teachers Retirement System acquired a new position in shares of Amneal Pharmaceuticals in the 1st quarter valued at $376,000. Y Intercept Hong Kong Ltd acquired a new position in shares of Amneal Pharmaceuticals in the 1st quarter valued at $136,000. Strs Ohio grew its position in shares of Amneal Pharmaceuticals by 158.5% in the 1st quarter. Strs Ohio now owns 10,600 shares of the company’s stock valued at $132,000 after buying an additional 6,500 shares during the last quarter. Finally, MQS Management LLC purchased a new position in shares of Amneal Pharmaceuticals in the 1st quarter valued at $325,000. 31.82% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Amneal Pharmaceuticals news, Director Deborah M. Autor sold 34,819 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $12.94, for a total transaction of $450,557.86. Following the completion of the sale, the director directly owned 93,660 shares of the company’s stock, valued at approximately $1,211,960.40. This trade represents a 27.10% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 17.30% of the stock is currently owned by corporate insiders.

Amneal Pharmaceuticals Stock Performance

Shares of NASDAQ:AMRX opened at $19.10 on Thursday. The company has a 50-day simple moving average of $15.99 and a 200-day simple moving average of $14.19. Amneal Pharmaceuticals, Inc. has a one year low of $7.66 and a one year high of $19.26. The stock has a market capitalization of $6.09 billion, a price-to-earnings ratio of 50.26 and a beta of 1.26.

Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) last announced its earnings results on Thursday, May 7th. The company reported $0.27 earnings per share for the quarter. Amneal Pharmaceuticals had a net margin of 4.01% and a negative return on equity of 313.96%. The business had revenue of $722.52 million during the quarter. As a group, research analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.92 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently weighed in on AMRX shares. Weiss Ratings downgraded Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, May 26th. UBS Group raised their price target on Amneal Pharmaceuticals from $19.00 to $23.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. Zacks Research lowered Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. Wall Street Zen upgraded Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, July 12th. Finally, Barclays increased their price objective on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a report on Wednesday, May 20th. Five research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Amneal Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $16.60.

View Our Latest Report on AMRX

Amneal Pharmaceuticals Profile

(Free Report)

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.